Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment. Overview of attention for article published in Journal of Dermatological Treatment, November 2013. D, Drexel H. Abstract. To assess cardiometabolic biomarkers in patients with psoriasis before and after etanercept treatment. Puig L, et al. The aim of this study is to assess cardiometabolic biomarkers in patients with psoriasis before and after etanercept treatment. Efficacy and cost-effectiveness of octenidine wound gel in the treatment of chronic venous leg ulcers in comparison to modern wound dressings. Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis. Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment.
Editorial; J Dermatolog Treat 2014 Feb; 25(1):1. Suh HS, Choi YS; A comparative study of low-fluence 1064-nm Q-switched Nd:YAG laser with or without chemical peeling using Jessner’s solution in melasma patients. Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment. This study compared the efficacy, tolerability and cost analysis of etanercept twice weekly for 12 weeks then once weekly for 12 weeks versus etanercept once. 17 Jan 2012 Results published in the Journal of Dermatological Treatment. In the PRISTINE trial (NCT00663052), a post hoc analysis was conducted of the effects of etanercept therapy on cardiometabolic biomarkers in subjects with psoriasis based on diabetes status. After-treatment changes in glycemic control markers are shown (table). Those with pre-diabetes or diabetes showed no overall worsening in glycemic control (HbA1c) and had slight increases in plasma insulin and the insulin-resistance measure HOMA-A. These findings suggest that etanercept therapy does not worsen glycemic control in these at-risk populations.
A major goal of the Gelfands research program is improving psoriasis patient outcomes in the skin and joints, while lowering the risk of diabetes, cardiovascular disease and mortality. The purpose of the VIP trials is to determine the impact of psoriasis treatment on key markers of cardiovascular risk such as lipid metabolism (HDL function) and aortic inflammation measured by 18-FDG-PET/CT. Patients with psoriasis are often affected by comorbidities, which largely influence treatment decisions. Cardiometabolic biomarkers in chronic plaque psoriasis before and after etanercept treatment.
Some psoriasis therapies may increase cardiovascular disease (CVD) and others may decrease CVD. Open Label Study Etanercept’s Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis. Serum Lipid Levels and Other Biomarkers of Cardiovascular Disease in Patients With Psoriasis. A Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis. Obesity also involves patients with inflammatory arthritis. BF percentage (as assessed by X-ray absorptiometry) seems to be higher in patients with PsA than in patients with psoriasis only and controls.10 Lower fat mass assessed by bioelectrical impedance was found in 28 patients with AS compared with 17 controls. Before 2000, application of conventional methods produced essential information about keratinocytes, blood vessels, and immune-related cells in psoriatic lesions, ultimately leading to the identification of unique psoriasis proteins, e. (3) assessment of larger patient cohorts, yielding greater statistical power after adjustments for multiplicity of testing, and (4) ongoing improvements in statistical methods for analyzing whole-genome transcripts. Recent studies have shown that psoriasis comorbidities (e.g., cardio-metabolic) significantly impact patient health, and it has been hypothesized that inflammatory products could potentially be synthesized in the skin and released into systemic circulation by diffusion through cutaneous endothelium (Davidovici et al, 2010).